p16-/Ki-67 in der Zervix-Zytologie: IndikationenIndications for p16/Ki-67 in cervical cytology

[1] Allia E(2015)Interpretation of p16INK4a/Ki-67 dual immunostaining for the triage of human papillomavirus-positive women by experts and nonexperts in cervical cytology Cancer Cytopathol 123 212-218

[2] Ronco G(2015)Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal papanicolaou cytology: PALMS study results Cancer Cytopathol 123 373-381

[3] Coccia A(2015)Performance of p16INK4a/Ki-67 immunocytochemistry for identifying CIN2+ in atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesions specimens: a Japanese Gynecologic Oncology Group study Int J Clin Oncol 20 134-142

[4] Bergeron C(2015)Das Prozedere bei auffälligen Befunden, Kommentar zur Münchner Nomenklatur III Frauenarzt 56 10-13

[5] Ikenberg H(2016)Use of cytology, E6/E7 mRNA, and p16INK4a-Ki-67 to define the management of Human Papillomavirus (HPV)-positive women in cervical cancer screening Am J Clin Pathol 145 35-45

[6] Sideri M(2013)p16/Ki-67 in the Management of HPV-positive, cytology-negative cases Verh Dtsch Ges Zyt 28 42-47

[7] Fujii T(2013)Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study J Natl Cancer Inst 105 1550-1557

[8] Saito M(2014)Improved abnormal pap smear triage using cervical cancer biomarkers J Low Genit Tract Dis 18 1-7

[9] Hasegawa T(2013)Dual immunostaining of cervical cytology specimens with atypical squamous cells for p16/Ki-67 does not exclude the existence of a high-grade squamous intraepithelial lesion Virchows Arch 463 689-696

[10] Griesser H(2012)CINtec® PLUS dual Immunostain: a triage tool for cervical pap smears with atypical squamous cells of undetermined significance and low grade squamous intraepithelial lesion Diagn Cytopathol 41 582-586

[1] Allia E(2015)Interpretation of p16INK4a/Ki-67 dual immunostaining for the triage of human papillomavirus-positive women by experts and nonexperts in cervical cytology Cancer Cytopathol 123 212-218

[2] Ronco G(2015)Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal papanicolaou cytology: PALMS study results Cancer Cytopathol 123 373-381

[3] Coccia A(2015)Performance of p16INK4a/Ki-67 immunocytochemistry for identifying CIN2+ in atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesions specimens: a Japanese Gynecologic Oncology Group study Int J Clin Oncol 20 134-142

[4] Bergeron C(2015)Das Prozedere bei auffälligen Befunden, Kommentar zur Münchner Nomenklatur III Frauenarzt 56 10-13

[5] Ikenberg H(2016)Use of cytology, E6/E7 mRNA, and p16INK4a-Ki-67 to define the management of Human Papillomavirus (HPV)-positive women in cervical cancer screening Am J Clin Pathol 145 35-45

[6] Sideri M(2013)p16/Ki-67 in the Management of HPV-positive, cytology-negative cases Verh Dtsch Ges Zyt 28 42-47

[7] Fujii T(2013)Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study J Natl Cancer Inst 105 1550-1557

[8] Saito M(2014)Improved abnormal pap smear triage using cervical cancer biomarkers J Low Genit Tract Dis 18 1-7

[9] Hasegawa T(2013)Dual immunostaining of cervical cytology specimens with atypical squamous cells for p16/Ki-67 does not exclude the existence of a high-grade squamous intraepithelial lesion Virchows Arch 463 689-696

[10] Griesser H(2012)CINtec® PLUS dual Immunostain: a triage tool for cervical pap smears with atypical squamous cells of undetermined significance and low grade squamous intraepithelial lesion Diagn Cytopathol 41 582-586